However, of the five anti‐PD‐1/PD‐L1 antibody drugs approved for cancer immunotherapy, two of them, atezolizumab and durvalumab, were first approved for the treatment of bladder cancer 59 (Table 1). This evidence concerns the gene PDCD1 and cancer.